• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可逆性激肽释放酶6抑制剂的可扩展合成与结构表征

Scalable synthesis and structural characterization of reversible KLK6 inhibitors.

作者信息

Baumann Andreas, Isak Daniel, Lohbeck Jasmin, Jagtap Pravin Kumar Ankush, Hennig Janosch, Miller Aubry K

机构信息

Cancer Drug Development Group, German Cancer Research Center (DKFZ) Im Neuenheimer Feld 280 69120 Heidelberg Germany

Structural and Computational Biology Unit, European Molecular Biology Laboratory (EMBL) 69117 Heidelberg Germany.

出版信息

RSC Adv. 2022 Sep 21;12(41):26989-26993. doi: 10.1039/d2ra04670a. eCollection 2022 Sep 16.

DOI:10.1039/d2ra04670a
PMID:36320846
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9490775/
Abstract

Scalable asymmetric syntheses of two kallikrein-related protease 6 (KLK6) inhibitors are reported. The inhibitors are assembled by linking enantiomerically enriched fragments amide bond formation, followed by conversion of a cyano group to an amidine. One fragment, an amine, was prepared using the Ellman auxiliary, and a lack of clarity in the literature regarding the stereochemical outcome of this reaction was solved X-ray crystallographic analysis of two derivatives. Complexes of the inhibitors bound to human KLK6 were solved by X-ray crystallography, revealing the binding poses.

摘要

报道了两种激肽释放酶相关蛋白酶6(KLK6)抑制剂的可扩展不对称合成。这些抑制剂通过对映体富集片段的酰胺键形成进行组装,随后将氰基转化为脒。其中一个片段,即胺,是使用埃尔曼助剂制备的,通过对两种衍生物的X射线晶体学分析解决了文献中关于该反应立体化学结果的不明确之处。通过X射线晶体学解析了抑制剂与人KLK6结合的复合物,揭示了结合模式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb08/9490775/d08984fb941b/d2ra04670a-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb08/9490775/fc5753e61545/d2ra04670a-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb08/9490775/61779ad9676e/d2ra04670a-s1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb08/9490775/4801bd787e09/d2ra04670a-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb08/9490775/9a40470e13d6/d2ra04670a-s2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb08/9490775/d08984fb941b/d2ra04670a-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb08/9490775/fc5753e61545/d2ra04670a-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb08/9490775/61779ad9676e/d2ra04670a-s1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb08/9490775/4801bd787e09/d2ra04670a-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb08/9490775/9a40470e13d6/d2ra04670a-s2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb08/9490775/d08984fb941b/d2ra04670a-f3.jpg

相似文献

1
Scalable synthesis and structural characterization of reversible KLK6 inhibitors.可逆性激肽释放酶6抑制剂的可扩展合成与结构表征
RSC Adv. 2022 Sep 21;12(41):26989-26993. doi: 10.1039/d2ra04670a. eCollection 2022 Sep 16.
2
A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering.通过组合工程开发的一种强力、抗蛋白水解的激肽释放酶相关肽酶 6(KLK6)抑制剂,用于癌症治疗。
J Biol Chem. 2018 Aug 17;293(33):12663-12680. doi: 10.1074/jbc.RA117.000871. Epub 2018 Jun 22.
3
Development of monoclonal antibodies to human kallikrein-related peptidase 6 (KLK6) and their use in an immunofluorometric assay for free KLK6.人激肽释放酶相关肽酶6(KLK6)单克隆抗体的研制及其在游离KLK6免疫荧光测定法中的应用。
Biol Chem. 2014 Sep;395(9):1119-26. doi: 10.1515/hsz-2014-0133.
4
Correction: Scalable synthesis and structural characterization of reversible KLK6 inhibitors.更正:可逆性激肽释放酶6抑制剂的可扩展合成及结构表征
RSC Adv. 2022 Oct 10;12(44):28677. doi: 10.1039/d2ra90102a. eCollection 2022 Oct 4.
5
Study of kallikrein-related peptidase 6 (KLK6) and its complex with α1-antitrypsin in biological fluids.生物体液中激肽释放酶相关肽酶6(KLK6)及其与α1-抗胰蛋白酶复合物的研究。
Clin Chem Lab Med. 2017 Aug 28;55(9):1385-1396. doi: 10.1515/cclm-2017-0017.
6
An advance on exploring N-tert-butanesulfinyl imines in asymmetric synthesis of chiral amines.N-叔丁基亚磺酰亚胺在手性胺不对称合成中的研究进展。
Acc Chem Res. 2008 Jul;41(7):831-40. doi: 10.1021/ar7002623. Epub 2008 Jun 6.
7
Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity.具有中性 P1 的去糖肽是激肽释放酶相关肽酶 6 的有效抑制剂,具有针对靶细胞的活性。
J Med Chem. 2018 Oct 11;61(19):8859-8874. doi: 10.1021/acs.jmedchem.8b01106. Epub 2018 Sep 28.
8
Activity of human kallikrein-related peptidase 6 (KLK6) on substrates containing sequences of basic amino acids. Is it a processing protease?人激肽释放酶相关肽 6(KLK6)在含有碱性氨基酸序列的底物上的活性。它是一种加工蛋白酶吗?
Biochim Biophys Acta Proteins Proteom. 2017 May;1865(5):558-564. doi: 10.1016/j.bbapap.2017.02.017. Epub 2017 Feb 28.
9
The autolytic regulation of human kallikrein-related peptidase 6.人组织激肽释放酶相关肽酶6的自溶调节
Biochemistry. 2007 May 1;46(17):5209-17. doi: 10.1021/bi6025006. Epub 2007 Apr 7.
10
Identification and analysis of mammalian KLK6 orthologue genes for prediction of physiological substrates.用于预测生理底物的哺乳动物KLK6直系同源基因的鉴定与分析。
Comput Biol Chem. 2008 Apr;32(2):111-21. doi: 10.1016/j.compbiolchem.2007.11.002. Epub 2007 Nov 29.

引用本文的文献

1
Assessing the performance of docking, FEP, and MM/GBSA methods on a series of KLK6 inhibitors.评估一系列 KLK6 抑制剂对接、自由能预测(FEP)和 MM/GBSA 方法的性能。
J Comput Aided Mol Des. 2023 Sep;37(9):407-418. doi: 10.1007/s10822-023-00515-3. Epub 2023 Jun 28.

本文引用的文献

1
An oral SARS-CoV-2 M inhibitor clinical candidate for the treatment of COVID-19.一种用于治疗 COVID-19 的口服 SARS-CoV-2 M 抑制剂临床候选药物。
Science. 2021 Dec 24;374(6575):1586-1593. doi: 10.1126/science.abl4784. Epub 2021 Nov 2.
2
Addition of Highly Polarized Organometallic Compounds to N-tert-Butanesulfinyl Imines in Deep Eutectic Solvents under Air: Preparation of Chiral Amines of Pharmaceutical Interest.在深共晶溶剂中空气条件下向 N-叔丁基亚磺酰亚胺中添加高极化有机金属化合物:制备有药物应用价值的手性胺。
ChemSusChem. 2020 Jul 22;13(14):3583-3588. doi: 10.1002/cssc.202001142. Epub 2020 Jun 29.
3
Kallikrein-6-Regulated Pathways Shed Light on New Potential Targets in Varicella Zoster Virus Infection.
激肽释放酶 6 调控途径揭示了水痘带状疱疹病毒感染新的潜在靶点。
J Invest Dermatol. 2020 Apr;140(4):741-742. doi: 10.1016/j.jid.2019.11.006.
4
Synthesis and Structure-Activity Relationships of N-(4-Benzamidino)-Oxazolidinones: Potent and Selective Inhibitors of Kallikrein-Related Peptidase 6.N-(4-苯甲脒基)-恶唑烷酮的合成及构效关系:激肽释放酶相关肽酶 6 的高效和选择性抑制剂。
ChemMedChem. 2020 Jan 7;15(1):79-95. doi: 10.1002/cmdc.201900536. Epub 2019 Nov 18.
5
Kallikrein-Mediated Cytokeratin 10 Degradation Is Required for Varicella Zoster Virus Propagation in Skin. Kallikrein-Mediated Cytokeratin 10 Degradation Is Required for Varicella Zoster Virus Propagation in Skin.
J Invest Dermatol. 2020 Apr;140(4):774-784.e11. doi: 10.1016/j.jid.2019.08.448. Epub 2019 Oct 15.
6
Enantioselective Imine Reduction Catalyzed by Phosphenium Ions.手性亚胺还原反应的磷翁离子催化作用。
J Am Chem Soc. 2019 Sep 11;141(36):14083-14088. doi: 10.1021/jacs.9b07293. Epub 2019 Aug 27.
7
Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity.具有中性 P1 的去糖肽是激肽释放酶相关肽酶 6 的有效抑制剂,具有针对靶细胞的活性。
J Med Chem. 2018 Oct 11;61(19):8859-8874. doi: 10.1021/acs.jmedchem.8b01106. Epub 2018 Sep 28.
8
Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease.评估激肽释放酶 6 作为阿尔茨海默病的横断面和纵向生物标志物。
Alzheimers Res Ther. 2018 Jan 29;10(1):9. doi: 10.1186/s13195-018-0336-4.
9
Specific microRNA-mRNA Regulatory Network of Colon Cancer Invasion Mediated by Tissue Kallikrein-Related Peptidase 6.组织激肽释放酶相关肽酶6介导的结肠癌侵袭特异性微小RNA-信使核糖核酸调控网络
Neoplasia. 2017 May;19(5):396-411. doi: 10.1016/j.neo.2017.02.003. Epub 2017 Apr 18.
10
Unleashing the therapeutic potential of human kallikrein-related serine proteases.释放人激肽释放酶相关丝氨酸蛋白酶的治疗潜力。
Nat Rev Drug Discov. 2015 Mar;14(3):183-202. doi: 10.1038/nrd4534. Epub 2015 Feb 20.